Safety, tolerability and blood-level testing of SV003 in healthy adults.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1 interventional trial in healthy adult volunteers to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SV003 versus placebo. Participating adults who meet BMI and weight criteria will receive SV003 or placebo under controlled conditions with medical monitoring. The protocol includes serial blood sampling and clinical assessments to measure drug levels and biological effects and to capture adverse events. Results will inform dosing and safety for later patient studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Body Mass Index (BMI): 18.5 ≤ Chinese participants ≤ 30 kg/m², 18.5 ≤ Caucasian participants ≤ 32 kg/m²; additionally, male participants must have a body weight ≥ 50 kg, and female participants ≥ 45 kg;
2. Healthy status: No evidence of active or chronic diseases in participants;
3. Ability to participate in the study, willingness to provide written informed consent, and compliance with study requirements.

Exclusion Criteria:

1. Subjects with a history of chronic diseases or currently presenting with clinically significant systemic diseases;
2. Subjects who have experienced a serious disease within 1 month prior to drug administration, or with any disease that may relapse immediately during or after the study;
3. Subjects with designated examination results reaching a specified value;
4. Subjects with abnormal laboratory test results deemed clinically significant by the investigator;
5. Subjects positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody;
6. Subjects with a history of drug abuse within the past 2 years, or with a positive urine drug screen on Day -1;
7. Subjects with a history of alcohol dependence within the past 2 years, or with a positive breath alcohol test result on Day -1;
8. Subjects with an average daily cigarette consumption of ≥ 5 cigarettes within 3 months prior to screening;
9. Subjects who have donated blood or lost blood ≥ 400 mL within 3 months prior to drug administration, or donated blood or lost blood ≥ 200 mL within 1 month, or with a history of blood product use;
10. Subjects with an allergic constitution, or with a history of allergy to the study drug, drugs of the same class or excipients;
11. Subjects who have participated in clinical studies of investigational drugs or medical devices within 3 months prior to drug administration;
12. Female subjects with a positive pregnancy test during the screening period or on Day -1, or who are breastfeeding;
13. Chinese female subjects who are postmenopausal or have an irregular menstrual cycle;
14. Female subjects of childbearing potential, or male subjects whose female partners are of childbearing potential, who refuse to adopt reliable contraceptive measures during the study and for 6 months after the last drug administration;
15. Any other factors that the investigator deems may render a subject unsuitable for study participation.

Where it's running

• Shanghai Xuhui Central Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Qian Chen
• Email: xhzxyy@xh.sh.cn
• Phone: 86-021-36682212

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How age affects germinal center responses after flu and rabies vaccines

  Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).

  Recruiting Phase 4 Washington University School of Medicine · St Louis, Missouri · NCT07914673

• Magnetic field maps with NV sensors for non-invasive heart measurements

  This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.

  Recruiting Robert Bosch GmbH · Renningen · NCT07908173

• Methylation analyses using home-based self-sampling in women with and without gynecological disease

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation markers that distinguish people with gynecological (pre-)cancers from cancer-free controls.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902388

• Omega-3 status in healthy adults: comparing different fish-oil and algae-oil products

  This study tests whether various fish-oil and algae-oil products can raise the Omega-3 Index in healthy adults who don’t eat much fatty fish.

  Recruiting Nordic Naturals · London, Ontario · NCT07900425

• A safe, carefully dosed test of TBD11 in healthy adults

  This phase 1 study tests TBD11 in healthy adults to see if it is safe and tolerable and to understand how it behaves in the body, including how it interacts with other medicines.

  Recruiting Phase 1 Gates Medical Research Institute · Bloemfontein · NCT07883226

• Fosmanogepix in healthy adults: how it may interact with other drugs and heart rhythm

  This study tests whether fosmanogepix (and its active form manogepix) changes how other medicines work in healthy adults.

  Recruiting Phase 1 Basilea Pharmaceutica · Groningen, Netherlands · NCT07881224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.